Liver Cirrhosis - Pipeline Review, H1 2018

Publisher Name :
Date: 20-Feb-2018
No. of pages: 88
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2018, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).

  • The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Liver Cirrhosis - Pipeline Review, H1 2018

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis - Overview
Liver Cirrhosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Cirrhosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Cirrhosis - Companies Involved in Therapeutics Development
Galectin Therapeutics Inc
Gilead Sciences Inc
Human Stem Cells Institute
International Stem Cell Corp
Novartis AG
Ocera Therapeutics Inc
Pharmicell Co Ltd
Rohto Pharmaceutical Co Ltd
VESSL Therapeutics Ltd
Liver Cirrhosis - Drug Profiles
7-E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADR-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCD-800 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-LC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gemacell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXHPC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit C/EBP-Beta for Pulmonary Fibrosis, Hepatic Injury and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate ZSCAN4 for Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLY-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Cirrhosis - Dormant Projects
Liver Cirrhosis - Discontinued Products
Liver Cirrhosis - Product Development Milestones
Featured News & Press Releases
Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Liver Cirrhosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H1 2018
Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2018
Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H1 2018
Liver Cirrhosis - Pipeline by International Stem Cell Corp, H1 2018
Liver Cirrhosis - Pipeline by Novartis AG, H1 2018
Liver Cirrhosis - Pipeline by Ocera Therapeutics Inc, H1 2018
Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H1 2018
Liver Cirrhosis - Pipeline by Rohto Pharmaceutical Co Ltd, H1 2018
Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H1 2018
Liver Cirrhosis - Dormant Projects, H1 2018
Liver Cirrhosis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Liver Cirrhosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Oligonucleotide Therapeutics Market 2018-2022
    Published: 13-Jun-2018        Price: US 3500 Onwards        Pages: 103
    About Oligonucleotide Therapeutics Oligonucleotides are short nucleotides sequences of DNA or RNA molecules called oligomers. Oligonucleotide therapeutics target and inhibit the expression of certain diseases-causing genes, thus forming a new class of therapeutics to treat chronic diseases. The analysts forecast Global Oligonucleotide Therapeutics Market to grow at a CAGR of 9.52% during the period 2018-2022. Covered in this report This repor......
  • Global Migraine Therapeutics Market 2018-2022
    Published: 13-Jun-2018        Price: US 3500 Onwards        Pages: 102
    About migraine therapeutics Migraine therapeutics caters to the treatment of acute or chronic migraine. It can be either preventive or abortive, that determines the treatment of migraine. The analysts forecast Global Migraine Therapeutics Market to grow at a CAGR of 5.38% during the period 2018-2022. Covered in this report This report covers the present scenario and the growth prospects of the migraine therapeutics market. To calcula......
  • Global Sclerotherapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 11-Jun-2018        Price: US 3480 Onwards        Pages: 135
    Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids. Scope of the Report: This report focuses on the Sclerotherapy in g......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Sclerotherapy Market 2018, Forecast to 2023
    Published: 11-Jun-2018        Price: US 4880 Onwards        Pages: 130
    Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. A medicine is injected into the vessels, which makes them shrink. It is used for children and young adults with vascular or lymphatic malformations. In adults, sclerotherapy is often used to treat spider veins, smaller varicose veins, and hemorrhoids. Scope of the Report: This report focuses on the Sclerotherapy in g......
  • Global Brachytherapy Afterloaders, Brachytherapy Seeds Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 09-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radioactive sources into the treatment site, to avoid risk of radiation exposure to clinical staff. Brachytherapy Seeds is radiation sources enclosed within a non-radioactive capsule. The common radiation sources are Iodine-125 Palladium-103 Cesium-137. Scope of the Report: This report focuses on the Brachytherapy Afterloaders, Brachytherapy Seeds in global market, especially in N......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Brachytherapy Afterloaders, Brachytherapy Seeds Market 2018, Forecast to 2023
    Published: 09-Jun-2018        Price: US 4880 Onwards        Pages: 130
    Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radioactive sources into the treatment site, to avoid risk of radiation exposure to clinical staff. Brachytherapy Seeds is radiation sources enclosed within a non-radioactive capsule. The common radiation sources are Iodine-125 Palladium-103 Cesium-137. Scope of the Report: This report focuses on the Brachytherapy Afterloaders, Brachytherapy Seeds in global market, especially in N......
  • United States Human Microbiome Therapeutics Market Report 2018
    Published: 04-Jun-2018        Price: US 3800 Onwards        Pages: 97
    In this report, the United States Human Microbiome Therapeutics market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and g......
  • Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market
    Published: 01-Jun-2018        Price: US 4995 Onwards        Pages: 125
    Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the world’s population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common symptoms of psoriasis include inflammation, swelling, and patches of red, itchy, flaky skin called skin lesions. The most common sites of involvement are the scalp, elbows and knees, followed by nails, hands, feet and trunk. It is estimated tha......
  • Global Acute Ischemic Stroke Therapeutics Market Professional Survey Report 2018
    Published: 01-Jun-2018        Price: US 3500 Onwards        Pages: 104
    This report studies Acute Ischemic Stroke Therapeutics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Bayer - Boehringer Ingelheim - Roche - Sanofi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs